Wuhan Keqian Biology Co (SHSE:688526) EBIT: ¥444.4 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688526 Wuhan Keqian Biology Co Ltd SHSE:688526
80 GF Score
Price ¥12.65
GF Value ¥16.91
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Wuhan Keqian Biology Co EBIT?

Wuhan Keqian Biology Co SHSE:688526 +0.56% 80 EBIT is ¥444.4 Mil as of Mar. 2026. GuruFocus rates SHSE:688526 with a GF Score™ of 80/100 and a GF Value™ of ¥16.91 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Wuhan Keqian Biology Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥90.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥444.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Wuhan Keqian Biology Co's annualized ROC % for the quarter that ended in Mar. 2026 was 11.20%. Wuhan Keqian Biology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 22.31%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Wuhan Keqian Biology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 11.14%.


Wuhan Keqian Biology Co  (SHSE:688526) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Wuhan Keqian Biology Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=354.4 * ( 1 - 12.67% )/( (2797.732 + 2727.843)/ 2 )
=309.49752/2762.7875
=11.20 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4789.205 - 272.397 - ( 1719.076 - max(0, 457.496 - 2927.075+1719.076))
=2797.732

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4824.574 - 217.015 - ( 1879.716 - max(0, 419.166 - 3110.002+1879.716))
=2727.843

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Wuhan Keqian Biology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=360.708/( ( (867.386 + max(730.348, 0)) + (839.836 + max(795.348, 0)) )/ 2 )
=360.708/( ( 1597.734 + 1635.184 )/ 2 )
=360.708/1616.459
=22.31 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(285.153 + 144.271 + 756.813) - (272.397 + 0 + 183.492)
=730.348

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(319.632 + 136.299 + 757.618) - (217.015 + 0 + 201.186)
=795.348

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Wuhan Keqian Biology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=444.374/3990.361
=11.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuhan Keqian Biology Co EBIT Related Terms


Wuhan Keqian Biology Co EBIT Historical Data

* Premium members only.

The historical data trend for Wuhan Keqian Biology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuhan Keqian Biology Co EBIT Chart

Wuhan Keqian Biology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 661.86 472.05 465.74 442.90 479.77

Wuhan Keqian Biology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 125.57 128.15 135.52 90.53 90.18

SHSE:688526 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Wuhan Keqian Biology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan Keqian Biology Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan Keqian Biology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Wuhan Keqian Biology Co's EV-to-EBIT falls into.


SHSE:688526
80GF Score
Wuhan Keqian Biology Co Ltd SHSE:688526
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wuhan Keqian Biology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥444.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥444.4 Mil mean?
Wuhan Keqian Biology Co (SHSE:688526) has a EBIT of ¥444.4 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Wuhan Keqian Biology Co.
Is Wuhan Keqian Biology Co's EBIT too high?
Wuhan Keqian Biology Co's current EBIT is ¥444.4 Mil. Overall, Wuhan Keqian Biology Co has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Wuhan Keqian Biology Co's EBIT compare to VRTX and REGN?
Wuhan Keqian Biology Co's EBIT of ¥444.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Wuhan Keqian Biology Co. Wuhan Keqian Biology Co's current EBIT is ¥444.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan Keqian Biology Co stock overvalued right now?
Based on GuruFocus' analysis, Wuhan Keqian Biology Co (SHSE:688526) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥16.91, compared to a current price of ¥12.65 — trading 25.2% below its estimated fair value. The current EBIT is ¥444.4 Mil. Wuhan Keqian Biology Co's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Wuhan Keqian Biology Co (SHSE:688526), the current EBIT is ¥444.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Wuhan Keqian Biology Co (SHSE:688526) Overvalued in 2026?

Based on GuruFocus' analysis, Wuhan Keqian Biology Co stock appears to be undervalued. The current stock price of ¥12.65 is trading 25.2% below its estimated GF Value™ of ¥16.91. GuruFocus considers Wuhan Keqian Biology Co to be Modestly Undervalued.

Key valuation signals for SHSE:688526:

  • EBIT: ¥444.4 Mil
  • GF Value™: ¥16.91 vs. price of ¥12.65 (25.2% below fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688526 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Wuhan Keqian Biology Co Business Description

Address No. 419, Gaoxin 2nd Road, Donghu New Technology Development Zone, Hubei Province, Wuhan, CHN, 430073
Wuhan Keqian Biology Co Ltd is engaged in research and development, production, sales and animal epidemic prevention technical services of veterinary biological products. The company's products include Combination plan; Vaccine for swine; Poultry vaccine; Pet vaccine; and Diagnostic reagent.
80GF Score

Get the complete analysis for SHSE:688526

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥12.65
Price
¥16.91
GF Value